Sunday
06.16.2024
10:00 AM
Login form
Search
Calendar
Entries archive

Africa Live News

Main » 2023 » October » 11 » Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa
9:27 AM
Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa

 

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. Under the terms of the agreement, Hikma has an exclusive license to commercialise Oregovomab in 18 Middle East and North Africa (MENA) countries. 

 

Oregovomab is a murine monoclonal antibody and a first-in-class anti-CA125 immunotherapy drug candidate. It is being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer. Oregovomab has obtained Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

 

“Ovarian cancer is ranked as the eighth most common cancer in women globally[1] and the first-line treatment for this disease has not changed for many years. We have been actively expanding our oncology portfolio through R&D and in-licensing, in order to address unmet medical needs in different types of cancer and bring renewed hope to cancer patients in the MENA region,” said Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA. “We believe Oregovomab can potentially improve the treatment outcomes for patients with advanced primary ovarian cancer. We are excited about the collaboration with CanariaBio as it will bring hope to our cancer patients in MENA and strengthen our oncology portfolio.”

 

About Hikma

 

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, MENA and Europe.

 

[1] World Cancer Research Fund International, available at https://www.wcrf.org/cancer-trends/ovarian-cancer-statistics/#:~:text=Latest%20ovarian%20cancer%20data,of%20ovarian%20cancer%20in%202020

 

Permalink

https://aetoswire.com/en/news/hikma101020223en

Contacts

Mona Abdallah

+ 962 6 5802900

MBAbdallah@Hikma.com

Views: 37 | Added by: africa-live | Rating: 0.0/0
Total comments: 0
Name *:
Email *:
Code *: